Akeso Collaborates with MSKCC to Initiate Phase II Trial of Cadonilimab Regimen for Gastric Cancer

Akeso, Inc. (9926.HK), a Hong Kong-listed biopharmaceutical company, announced a collaboration with Memorial Sloan Kettering Cancer Center (MSKCC) to advance a Phase II clinical trial. The study will evaluate a combination regimen based on cadonilimab, an immunotherapy drug targeting PD-1/CTLA-4 pathways, for perioperative treatment of gastric cancer. The trial represents a significant step in the company's development pipeline, aiming to improve treatment options for gastric cancer patients.

The partnership underscores Akeso's focus on innovative immunotherapies and its commitment to advancing cancer treatment through clinical research. The trial is expected to provide important data on the safety and efficacy of the cadonilimab combination in this setting.

This development could potentially impact Akeso's stock performance positively if the trial results are favorable, as it may lead to further clinical progress and eventual commercialization. However, as the trial is still in early phases, the direct market impact remains uncertain until more data is available.